Catequentinib

Anlotinib

Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 3Active

BB

71/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 62/ 100
Competitive Position: 89/ 100

Competitive context

9 Active assets in the Anlotinib cohort.

Asset / Sponsor	Phase	Rating
Benmelstobart Nanfang Hospital, Southern Medical University	Phase 3	BB
Penpulimab Degan Lu	Phase 3	B
Irinotecan First People's Hospital of Hangzhou	Phase 2	CCC
Docetaxel First People's Hospital of Hangzhou	Phase 2	CCC
Carboplatin Wenjun Cheng	Phase 2	CCC

View all 19 →

Same molecule, other indications

Catequentinib is also rated in:

refractory malignant neoplasmDormant

BB

Indicative ·

70 / 100

kidney cancerDormant

BB

Indicative ·

66 / 100

non-small cell squamous lung carcinomaDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.